Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth


Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):


Corporate Social Responsibility / Socially Responsible Investment

The position of Sanofi among the world leaders in the pharmaceutical industry confers responsibilities towards patients throughout the world, but also towards partners, employees and shareholders.


Corporate Social Responsibility (CSR)

Sanofi has long engaged in multiple initiatives around the world that testify to its deep-rooted sense of corporate responsibility. It also plays a role in major international initiatives to strengthen the commitment to responsibility of business in general. Sanofi is a signatory to the Global Compact, a member of CSR Europe, and a founding member of EDH (Entreprises pour les droits de l’Homme; Companies for Humans Rights). In order to strengthen and harmonize this commitment, Sanofi created a Corporate Social Responsibility division in 2009. Operating cross-functionally within the Company’s General Management division, it is tasked with coordinating sustainable development actions as well as those dedicated to Diversity and Disability, Access to Medicines, and Humanitarian Partnerships. It also coordinates other structures concerned with the welfare of employees and their families.

Sustainable development offers a key opportunity for Sanofi to enhance its business performance. In an effort to make the environment, social issues and business targets interoperate better on a daily basis, the Company is focusing on innovation to build competitive advantages and enhance dialogs with its stakeholders. Its sustainable development policy has been organized into four initiatives – Patient, People, Ethics and Planet – to deliver a clear, understandable message to its internal and external constituencies.

Further information:


Corporate governance

Sanofi is committed to good corporate governance in order to provide transparent information to our shareholders.

To respond to the public’s expectations concerning corporate governance and sustainable development, the office of Chairman of the Board and the office of Chief Executive Officer have been separated since January 1, 2007.

At its meeting held on December 17, 2008, the Board of Directors examined the AFEP-MEDEF recommendations dated October 6, 2008 concerning Executive Directors compensation for listed companies. The Board of Directors considers that these recommendations are consistent with the company's corporate governance approach.

Therefore, the Board of Directors decided that Sanofi will refer to the amended AFEP-MEDEF code for the preparation of the report of the Chairman of the Board of Directors pursuant to article L. 225-37 of the French Commercial Code.

Further information:


Socially Responsible Investment (SRI)

The Corporate Social Responsibility division, in coordination with the Investor Relations department, is in charge of the information of socially responsible investors and rating agencies. Both assess companies according to social, environmental, economic and governance criteria. 

Rating agencies choose those companies with proactive policies for responsibly managing economic, environmental and social aspects of doing business, via their indexes.

Sanofi is listed in one of the most important sustainable indexes, the Dow Jones Sustainability Index, for the 9th consecutive year in 2015. Sanofi is also a member of several key indexes such as FTSE4Good, Stoxx Sustainability Indices, Ethibel Excellence or Access to Medicine Index.

Further information:


© Sanofi 2004-2017 - All rights reserved - Update: March 06, 2017

  • Site complies with W3C WCAG 2.0 (new window, in english)